Boston Scientific’s Upgraded Vercise DBS Software Earns FDA Nod

Boston Scientific has earned U.S. Food and Drug Administration (FDA) approval for its Vercise Neural Navigator 5 software, which is used with the company’s Vercise Genus deep brain stimulation (DBS) systems).
 
When used together, the new software can generate simple and actionable data for efficient programming to treat people living with Parkinson’s disease or essential tremor.
 
“The ability to see the precise placement of DBS Systems enables us to target therapy to meet individual needs,” Mustafa Saad Siddiqui, M.D., professor of Neurology and Neurosurgery at Wake Forest School of Medicine and medical director of the DBS program at Atrium Health Wake Forest Baptist, told the press. “The new features in the Vercise Neural Navigator 5 are expected to help further reduce the time needed to adjust stimulation and minimize potential side effects, allowing us to optimize treatment benefits for each patient.”
 
Vercise Neural Navigator 5 software with STIMVIEW XT tech is the latest addition to Boston Scientific’s image-guided programming solutions. The software was developed in partnership with software-driven medtech firm Brainlab and show reduction in DBS programming time by 56%. The software also offers real-time visualization and stimulation of unique brain anatomy.
 
The software also has an enhanced user interface to display patient data in simplified format, and provides clinicians with advanced settings for increased delivery of therapy. Vercise Neural Navigator 5 was engineered to enable more flexibility to better manage evolving needs of each patient at any stage of their condition.
 
“Developing meaningful tools to help physicians provide personalized treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions,” said Jim Cassidy, president, Neuromodulation, Boston Scientific. “Providing effective DBS therapy is complex and can be time-consuming. This software will help streamline the process and allow for more doctor-patient interaction time.”